LEI: 213800OTQ44T555I8S71
11 September 2019
Augmentum Fintech plc
(the ‘Company’)
Result of Annual General Meeting
Following the Annual General Meeting of the Company held at 9.30 a.m. today, the Board is pleased to announce that the resolutions put to Shareholders were passed.
The proxy voting figures are shown below:
Resolutions | Votes For |
% | Votes Against | % | Total Votes Cast | Votes Withheld |
Ordinary Resolutions | ||||||
To receive the Annual Report and Financial Statements for the period from incorporation on 19 December 2017 to 31 March 2019. | 21,673,328 | 99.92% | 16,402 | 0.08% | 21,689,730 | 19,671 |
To elect Neil England as a Director of the Company. | 21,672,317 | 99.87% | 28,009 | 0.13% | 21,700,326 | 9,075 |
To elect Karen Brade as a Director of the Company. | 21,670,800 | 99.87% | 28,009 | 0.13% | 21,698,809 | 10,592 |
To elect David Haysey as a Director of the Company. | 21,672,317 | 99.87% | 28,009 | 0.13% | 21,700,326 | 9,075 |
To receive and approve the Directors’ Remuneration Report for the period ended 31 March 2019. | 21,645,277 | 99.85% | 31,819 | 0.15% | 21,677,096 | 32,305 |
To approve the Directors’ Renumeration Policy. | 21,638,197 | 99.82% | 38,899 | 0.18% | 21,677,096 | 32,305 |
To appoint PricewaterhouseCoopers LLP as Auditors of the Company and to authorise the Audit Committee to determine their remuneration. | 21,661,573 | 99.80% | 44,228 | 0.20% | 21,705,801 | 3,600 |
Special Business | ||||||
To authorise the Directors to disapply pre-emption rights on the sale of Treasury shares and to sell Treasury shares at a narrower discount than that at which they were bought (Special Resolution). | 21,633,376 | 99.80% | 43,860 | 0.20% | 21,677,236 | 32,165 |
To authorise the Company to make market purchases of Ordinary shares in the Company. (Special Resolution). |
21,647,351 | 99.85% | 33,485 | 0.15% | 21,680,836 | 28,565 |
That the Directors be permitted to call general meetings (other than annual general meetings) on 14 clear days’ notice. (Special Resolution). |
21,684,893 | 99.89% | 23,497 | 0.11% | 21,708,390 | 1,011 |
Notes:
Any proxy votes which are at the discretion of the Chairman have been included in the "for" total. A vote withheld is not a vote in law and is not counted in the votes for or against a resolution.
At the record date for the Annual General Meeting the total number of Ordinary Shares of 1p each in issue was 117,051,911 and this was the total number of Ordinary Shares with voting rights in the Company.
The proxy voting figures will shortly also be available on the Company's website at http://www.augmentum.vc/
The full text of the resolutions can be found in the Notice of Annual General Meeting, which is available for viewing at the National Storage Mechanism and can be located at http://www.morningstar.co.uk/uk/NSM and on the Company’s website, http://www.augmentum.vc/.
In accordance with Listing Rule 9.6.2 and Listing Rule 9.6.3, the full text of the special business resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/nsm. The special business resolutions will additionally be filed with Companies House.
Terms not otherwise defined in this announcement have the meaning given to them in the Notice of Meeting.
For further information, please contact:
Augmentum Tim Levene, Portfolio Manager Nigel Szembel, Investor Relations |
+44 (0)20 3961 5420 +44 (0)7802 362088 nigel@augmentum.vc |
Peel Hunt Liz Yong Luke Simpson |
+44 (0)20 7418 8900 |
Frostrow Victoria Hale, Company Secretary |
+44 (0)20 3170 8732 info@frostrow.com |
Notes to Editors
Augmentum Fintech plc is one of Europe’s leading venture capital investors focusing exclusively on the fintech sector. Augmentum Fintech invests in fast growing fintech businesses that are disrupting the banking, insurance, asset management and wider financial services sectors. Augmentum Fintech is the UK’s only publicly listed investment company focusing on the fintech sector, having launched on the main market of the London Stock Exchange in 2018, giving businesses access to patient capital and support, unrestricted by conventional fund timelines.